Cardiovascular risks of COX inhibition: current perspectives

Abstract

Background: NSAIDs are among the most commonly used pharmacotherapeutic agents worldwide. As the long-term use of these drugs is associated with serious gastrointestinal side effects, a new subgroup of COX-2 selective NSAIDs was developed. It was thought that the therapeutic strategy underlying the development of these newer compounds would enable them to provide the same analgesic and anti-inflammatory benefits as those of their traditional counterparts but perhaps offer a much safer gastrointestinal profile. Much scientific data has accumulated over the last few years, however, raising concerns regarding the increased cardiovascular complications associated with the use of COX-2 selective NSAIDs, and perhaps of the traditional NSAIDs as well.

Objective: To review current and emerging evidence related to the cardiovascular effects of COX inhibitors and examine the clinical implications.

Method: We studied data from basic clinical research, non-randomized analyses, and randomized trials of COX inhibitors that investigated their cardiovascular effects.

Conclusion: Both COX-2 selective and traditional NSAIDs are associated with a moderately increased risk of cardiovascular events.